Amneal Pharmaceuticals, Inc. (AMRX)

NMS – Real Time Price. Currency in USD

17.66

+0.56 (3.27%)

At close: Aug 12, 2026, 3:59 PM EDT

17.68

+0.02 (0.11%)

After-hours: Aug 12, 2026, 4:36 PM EDT

12.08.2026

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.

12.08.2026

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.

12.08.2026

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.

11.08.2026

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

10.08.2026

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal's growth profile into the 2030s BRIDGEWATER, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization.

07.08.2026

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?

Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Videos

No Data

There is no data to display

Press releases

10.08.2026

Amneal Pharmaceuticals, Inc. (AMRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Amneal Pharmaceuticals, Inc. (AMRX)

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?

Videos

No Data

Press releases

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?

Videos

No Data

Press releases

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Search stocks

Amneal Pharmaceuticals, Inc. (AMRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Amneal Pharmaceuticals, Inc. (AMRX)

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?

Videos

No Data

Press releases

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?

Videos

No Data

Press releases

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader